9-ING-41 in Patients With Advanced Cancers

NCT03678883 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Pancreatic Cancer
Sarcoma
Renal Cancer
Refractory Cancer
Refractory Neoplasm
Refractory Non-Hodgkin Lymphoma
Pancreatic Adenocarcinoma
Resistant Cancer
Neoplasm Metastasis
Neoplasm of Bone
Neoplasm, Breast
Neoplasm of Lung
Neoplasms,Colorectal
Neoplasms Pancreatic
Malignant Glioma
Malignancies
Malignancies Multiple
Bone Metastases
Bone Neoplasm
Bone Cancer
Pancreas Cancer
Pancreatic Neoplasms
Breast Neoplasms
Acute T Cell Leukemia Lymphoma

Interventions

DRUG: 9-ING-41
DRUG: Gemcitabine - 21 day cycle
DRUG: Doxorubicin.
DRUG: Lomustine
DRUG: Carboplatin.
DRUG: Nab paclitaxel.
DRUG: Paclitaxel.
DRUG: Gemcitabine - 28 day cycle
DRUG: Irinotecan

Sponsor

Actuate Therapeutics Inc.